The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2022 | The importance of treatment sequencing in CLL
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, comments on the importance of sequencing treatments in patients with chronic lymphocytic leukemia (CLL) to improve the duration and quality of remission, and highlights the possibility of combining different agents. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
